

DOCKET NUMBERS: **VAND-0189-PV, VAND-0189-PV2, VAND-0189-PV3**

ASSIGNMENT

Whereas, we, the below named and undersigned inventors, owners of the entire right and interest in the invention and further identified by the Docket Numbers provided above in the header of this Assignment, for which applications for United States Patents were filed having:

US Provisional Application No.: 62/947,774, filed December 13, 2019
Liquid Tasimelteon Formulation

and

US Provisional Application No.: 62/972,902, filed February 11, 2020
Liquid Tasimelteon Formulations and Methods of Use Thereof

and

US Provisional Application No.: 63/119,488, filed November 30, 2020
Liquid Tasimelteon Formulations and Methods of Use Thereof

Whereas, **Vanda Pharmaceuticals Inc.**, a corporation of Delaware, having a place of business at **2200 Pennsylvania Avenue NW, Suite 300-E, Washington, D.C. 20037** (herein referred to as "ASSIGNEE"), desires to acquire, and we desire to grant to ASSIGNEE, our entire worldwide right, title, and interest in and to the Invention and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, we ("ASSIGNORS") hereby sell or have sold, assign or have assigned, and otherwise transfer or have transferred to **Vanda Pharmaceuticals Inc.** (the "ASSIGNEE"), its successors, legal representatives, and assigns, our individual and collective entire worldwide right, title, and interest in and to the Invention, the above-identified United States patent applications, and any and all other patent applications and patents for the Invention which may be applied for or granted therefor in the United States and in all foreign countries and jurisdictions, including all divisions, continuations, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, we hereby authorize and request the Director of the United States Patent and Trademark Office to issue any United States Patent, and foreign patent authorities to issue any foreign patent, granted for the Invention, to ASSIGNEE, its successors, legal representatives, and assigns, our entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by us had this Assignment not been made; and we agree to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the Invention and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, or assigns.

DOCKET NUMBERS: **VAND-0189-PV, VAND-0189-PV2, VAND-0189-PV3**

We acknowledge our prior and ongoing obligations to sell, assign, and transfer our rights under this Assignment to ASSIGNEE, and are unaware of any reason why we may not have the full and unencumbered right to sell, assign, and transfer our rights hereby sold, assigned, and transferred, and have not executed, and will not execute, any document or instrument in conflict herewith. We also hereby grant ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Assignment any further identification (including, but not limited to, patent Application Number) which may be necessary or desirable for recordation of this Assignment. This Assignment is governed by the substantive laws of the State of New York, and any disputes will be resolved in a New York state court or federal court sited in New York.

Deepak Phadke

Deepak Phadke

Deepak Phadke (Dec 7, 2020 09:26 EST)

Signature

Dec 7, 2020

Date

Mihael Polymeropoulos

Mihael Polymeropoulos

Signature

12/9/2020 | 1:35 PM PST

Date

VAND-0189-PV_VAND-0189-PV2_VAND-0189-PV3_Assignment_

Final Audit Report

2020-12-07

Created:	2020-12-06
By:	Steve Swinton (sswinton@hoffmanwarnick.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAjn41ncTvd-Jmij0v20jUt2pLSV--i9kg

"VAND-0189-PV_VAND-0189-PV2_VAND-0189-PV3_Assignme nt_" History



Document created by Steve Swinton (sswinton@hoffmanwarnick.com)

2020-12-06 - 8:49:50 PM GMT- IP address: 67.240.76.242



Document emailed to Deepak Phadke (deepak.phadke@vandapharma.com) for signature

2020-12-06 - 8:51:47 PM GMT



Email viewed by Deepak Phadke (deepak.phadke@vandapharma.com)

2020-12-06 - 10:06:11 PM GMT- IP address: 73.185.241.82



Document e-signed by Deepak Phadke (deepak.phadke@vandapharma.com)

Signature Date: 2020-12-07 - 2:26:28 PM GMT - Time Source: server- IP address: 73.185.241.82



Agreement completed.

2020-12-07 - 2:26:28 PM GMT